<DOC>
	<DOC>NCT00265031</DOC>
	<brief_summary>This study is designed to test (1) whether the BEACOPP dosage can be reduced to baseline in the last 4 cycles without loss of effectiveness, and (2) whether consolidating irradiation is necessary following effective chemotherapy.</brief_summary>
	<brief_title>HD12 for Advanced Stages</brief_title>
	<detailed_description />
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Hodgkin´s lymphoma (histologically proven) CS(PS) IIB with one or both of the risk factors: 1. bulky mediastinal mass (&gt; 1/3 of maximum transverse thorax diameter) 2. extranodal involvement CS(PS) III, IV written informaed consent Leukocytes &lt;3000/microl Platelets &lt;100000/microl Hodgkin´s Disease as "composite lymphoma" Activity index (WHO) &lt; grade 2</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Hodgkin´s Lymphoma</keyword>
	<keyword>advanced stages</keyword>
</DOC>